Phil McKernan - Basilea Pharmaceutica International Ltd

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 5 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Derazantinib Alone and with Atezolizumab in Metastatic Urothelial Carcinoma with Activating FGFR Aberrations

Andrea Necchi,Rodryg Ramlau,Alejandro Falcon Gonzalez,Arvind Chaudhry,Tilman Todenhoefer,Rana Tahbaz,Elisa Fontana,Patrizia Giannatempo,Jean-Laurent Deville,Damien Pouessel,Shinkyo Yoon,Thomas Powles, Mathieu Bernat, Manuel Hackl,Michalina Marszewska,Phil McKernan,Mikael Saulay, Federica Scaleia,Marc Engelhardt,Yohann Loriot,Arlene Siefker-Radtke,Maria De Santis

JNCI CANCER SPECTRUMno. 3 (2024)

Cited0Views0WOSBibtex

Derazantinib: an Investigational Drug for the Treatment of Cholangiocarcinoma

Stephan Braun,Paul McSheehy,Karine Litherland,Phil McKernan,Nicole Forster-Gross,Felix Bachmann, Mahmoud El-Shemerly,Miryana Dimova-Dobreva, Inessa Polyakova, Manuel Hackl,Ping Zhou,Heidi Lane,Laurenz Kellenberger,Marc Engelhardt

Expert opinion on investigational drugsno. 11 (2021): 1071-1080

Cited13Views0WOSBibtex

Phase 1/2a Study of BAL101553, a Novel Tumor Checkpoint Controller (TCC), Administered As 48-Hour Infusion in Adult Patients with Advanced Solid Tumors

Markus Joerger,Ioannis Metaxas,Anastasios Stathis,Dagmar Hess,Michael Thomas Mark,Franziska Hutter,Nicole Levy,Silvia Stuedeli,Simona Berardi, Michele Landau-Salzberg,Marc Frederick Engelhardt,Patrice Larger,Thomas Kaindl, Peter Hafner,Phil McKernan,Heidi A. Lane,Roger Anton Fredy Von Moos,Cristiana Sessa

Journal of clinical oncology（2018）

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn